Eurofins Scientific will acquire ViraCor-IBT Laboratories for $255 million.
Eurofins Scientific has signed a definitive agreement to acquire ViraCor-IBT Laboratories, a provider of specialty diagnostic testing, including biologic and molecular testing, from majority owner Ampersand Capital and other shareholders for approximately $255 million, subject to post-closing adjustments.
Eurofins reports that the acquisition will strengthen both its pharmaceutical and genomic service offerings and establish a presence in the specialty clinical testing services for infectious disease, immunology, allergy, HLA, and serology. The transaction also includes retaining VIBT’s 270 employees.
Upon closing of the transaction the company will continue to be known as ViraCor-IBT Laboratories. Completion of the transaction is expected in the next 60 days.
Source: Eurofins Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.